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Abstract
AIM: To investigate the proteome changes of stem 
cells due to ciclopirox olamine (CPX) treatment com-
pared to control and retinoic acid treated cells.
METHODS: Stem cells (SCs) are cells, which have the 
ability to continuously divide and differentiate into vari-
ous other kinds of cells. Murine embryonic stem cells 
(ESCs) and multipotent adult germline stem cells (maG-
SCs) were treated with CPX, which has been shown 
to have an antiproliferative effect on stem cells, and 
compared to stem cells treated with retinoic acid (RA), 
which is known to have a differentiating effect on stem 
cells. Classical proteomic techniques like 2-D gel elec-
trophoresis and differential in-gel electrophoresis (DIGE) 
were used to generate 2D protein maps from stem cells 
treated with RA or CPX as well as from non-treated 
stem cells. The resulting 2D gels were scanned and the 
digitalized images were collated with the help of Delta 
2D software. The differentially expressed proteins were 
analyzed by a MALDI-TOF-TOF mass spectrometer, and 
the identified proteins were investigated and catego-
rized using bioinformatics.
RESULTS: Treatment of stem cells with CPX, a syn-
thetic antifungal clinically used to treat superficial my-
coses, resulted in an antiproliferative effect in vitro , 
without impairment of pluripotency. To understand 
the mechanisms induced by CPX treatments which re-
sults in arrest of cell cycle without any marked effect 
on pluripotency, a comparative proteomics study was 
conducted. The obtained data revealed that the CPX 
impact on cell proliferation was accompanied with a 
significant alteration in stem cell proteome. By peptide 
mass fingerprinting and tandem mass spectrometry 
combined with searches of protein sequence databases, 
a set of 316 proteins was identified, corresponding to a 
library of 125 non-redundant proteins. With proteomic 
analysis of ESCs and maGSCs treated with CPX and RA, 
we could identify more than 90 single proteins, which 
were differently expressed in both cell lines. We could 
highlight, that CPX treatment of stem cells, with sub-
sequent proliferation inhibition, resulted in an altera-
tion of the expression of 56 proteins compared to non-
treated cells, and 54 proteins compared to RA treated 
cells. Bioinformatics analysis of the regulated proteins 
demonstrated their involvement in various biological 
processes. To our interest, a number of proteins have 
potential roles in the regulation of cell proliferation 
either directly or indirectly. Furthermore the classifica-
tion of the altered polypeptides according to their main 
known/postulated functions revealed that the majority 
of these proteins are involved in molecular functions 
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like nucleotide binding and metal ion binding, and bio-
logical processes like nucleotide biosynthetic processes, 
gene expression, embryonic development, regulation 
of transcription, cell cycle processes, RNA and mRNA 
processing. Proteins, which are involved in nucleotide 
biosynthetic process and proteolysis, were downregu-
lated in CPX treated cells compared to control, as well 
as in RA treated cells, which may explain the cell cycle 
arrest. Moreover, proteins which were involved in cell 
death, positive regulation of biosynthetic process, re-
sponse to organic substance, glycolysis, anti-apoptosis, 
and phosphorylation were downregulated in RA treated 
cells compared to control and CPX treated cells. 
CONCLUSION: The CPX treatment of SCs results in 
downregulation of nucleotide binding proteins and leads 
to cell cycle stop without impairment of pluripotency. 
© 2013 Baishideng. All rights reserved.
Key words: Stem cells; Differentiation; Hypusination; 
Ciclopirox olamine; Proteomics; Retinoic acid
Dihazi GH, Bibi A, Jahn O, Nolte J, Mueller GA, Engel W, Di-
hazi H. Impact of the antiproliferative agent ciclopirox olamine 
treatment on stem cells proteome. World J Stem Cells 2013; 5(1): 
9-25  Available from: URL: http://www.wjgnet.com/1948-0210/
full/v5/i1/9.htm  DOI: http://dx.doi.org/10.4252/wjsc.v5.i1.9
INTRODUCTION
Stem cells (SCs) are cells, which are found in all multicel-
lular organisms, which can continuously divide and dif-
ferentiate into various specialized cell types and can also 
self-renew to produce more stem cells[1]. The therapeutic 
use of  embryonic stem cells (ESCs) has been constrained 
by problems caused by immune rejection in the patient 
as well as ethical issues associated with the use of  embry-
os[2]. Spermatogonial stem cells (SSCs) are self-renewing 
single cells located in the periphery of  the seminiferous 
tubules whose continuous division maintain spermato-
genesis throughout the life of  a male individual[3]. SSCs 
were isolated from murine testis and cultured for the 
first time in 2006[4]. The pluripotency and plasticity of  
these cultured cells, named multipotent adult germline 
stem cells (maGSCs), were proven to be similar to ESCs. 
The ESC-like nature of  maGSCs was confirmed on the 
microRNA level[5], on the transcriptome level[6] and on 
the proteome level[7]. In a recent study, we investigated 
the effects of  retinoic acid (RA) treatment on the protein 
expression profiles of  maGSCs and ESCs[8]. The study 
revealed the important role of  Eif5a and its hypusination 
for stem cell differentiation and proliferation.
Eif5a is a universal translation elongation factor which 
is highly conserved in all cells. Eif5a has been shown to 
be associated with translation, viability and proliferation 
processes[9-12]. It is the only eukaryotic protein known to 
have the unusual amino acid hypusine. Hypusine is es-
sential to the function of  Eif5a and is involved in protein 
biosynthesis by promoting the formation of  the first pep-
tide bond and translation elongation[13]. The activation of  
Eif5a is controlled by a unique post-translational modifi-
cation called hypusination. It occurs in two steps which 
are controlled by two different enzymes[14,15], which inac-
tivation can lead to hypusination inhibition. Ciclopirox 
olamine (CPX), the ethanolamine salt of  6-cyclohexyl-
1-hydroxy-4-methylpyridin-2(1H)-one, is a hypusination 
inhibitor that controls the second step of  the modifica-
tion, which is catalyzed by deoxyhypusine hydroxylase[14].
CPX, a synthetic antifungal agent, has been used topi-
cally to treat fungal and yeast infection of  skin or mucosa 
for more than 20 years[16-19]. Apart from its antimycotic 
activity, CPX is also effective against both gram-positive 
and gram-negative bacteria[20]. CPX might also serve as 
an alternative to recombinant vascular endothelial growth 
factor (VEGF) treatment or to VEGF gene therapy for 
therapeutic angiogenesis[21]. The effect of  CPX on sev-
eral Saccharomyces cerevisiae mutants has been screened and 
tested, and it was suggested that CPX may exert its effect 
by disrupting DNA repair, DNA replication, cell division 
signals and a defect in mitotic spindle function. Further-
more CPX can influence the regulation of  many pro-
cesses, including signal transduction, transcription, cell di-
vision, and development[22]. Recent studies demonstrated 
CPX as a potential anti-cancer agent for the treatment of  
malignancies, including leukemia and myeloma[23-25]. How-
ever, the mechanism of  CPX as a drug in angiogenesis 
and tumor treatment is poorly understood. CPX works 
as an inhibitor of  the iron-dependent enzymes due to its 
role as a chelator of  intracellular iron[22,23]. Other stud-
ies reported the inhibition of  HIV-1 gene expression by 
CPX[26], the importance of  Eif5a in embryogenesis and 
cell differentiation[27], in hepatocellular carcinoma[28] and 
in diabetes[29]. CPX has also been used as an inhibitor of  
hypusination. 
In a recent study, the effect of  CPX on the cellular 
viability and proliferation of  ESCs and maGSCs was 
investigated. CPX treatment of  the stem cells resulted in 
an antiproliferative effect on ESCs and maGSCs in vitro, 
but did not affect the cell pluripotency[8]. The inhibitory 
effect of  CPX on cell differentiation was reversible and 
was not associated to apoptosis. The ESCs were found to 
be more sensitive to CPX than the maGSCs.
The aim of  this study was to investigate the proteome 
changes of  ESCs and maGSCs accompanying the treat-
ment with CPX and subsequent inhibition of  hypusina-
tion using classical proteomic techniques like 2-DE, 
DIGE and MS. 2D protein maps were generated from 
control cells and cells treated either with RA or CPX. 
The resulting protein maps were compared to each other 
and the differentially expressed proteins were investigated 
using bioinformatics. We could highlight that a treatment 
with CPX, involving proliferation inhibition, resulted in 
an alteration of  the expression of  56 proteins compared 
to non-treated cells, and 54 proteins compared to RA 
treated cells. The majority of  these proteins are involved 
in nucleotide binding and nucleotide biosynthetic pro-
10 January 26, 2013|Volume 5|Issue 1|WJSC|www.wjgnet.com
cesses, metal binding, DNA binding, and other processes 
which have been linked to CPX.
MATERIALS AND METHODS
Derivation and culture of maGSC and ESC lines 
The derivation and culture of  maGSCs 129/Sv was 
described previously[4]. In brief, testes from adult mice 
were isolated and digested using collagenase. Single cell 
suspension was derived after trypsin digestion followed 
by the culture of  the testis suspension cells on a mouse 
embryonic fibroblasts (MEFs) feeder layer in the pres-
ence of  GDNF. After appearance of  morphological 
ES-like cells, the colonies were picked and expanded in 
standard ES cell conditions. In this case, the maGSC line 
was generated without genetic selection, only by morpho-
logical criteria. The ESC R1 line was derived from the 
129/Sv mouse[30]. To maintain maGSCs and ESCs in an 
undifferentiated state, the cells were cultured under stan-
dard ESC culture conditions: DMEM (PAN, Aidenbach, 
Germany) supplemented with 20% fetal calf  serum (PAN, 
Aidenbach, Germany), 2 mmol/L L-glutamine (PAN, 
Aidenbach, Germany), 50 mmol/L β-mercaptoethanol 
(Gibco/Invitrogen, Eggenstein, Germany), 1 × non-es-
sential amino acids (Gibco/Invitrogen), sodium pyruvate 
(Gibco/Invitrogen), and penicillin/streptomycin (PAN, 
Aidenbach, Germany). ESCs and maGSCs were cultured 
on a feeder layer of  mitomycin C-inactivated MEFs in 
the presence of  1000 U/mL recombinant mouse leuke-
mia inhibitory factor (LIF) (Chemicon, Temecula, United 
States). ESCs were isolated as described previously, and 
male ESC lines were identified and selected by PCR am-
plification of  Sry gene-specific sequences[31,32]. In order 
to differentiate maGSCs and male ESCs, the cells were 
plated on gelatin-coated dishes and culture medium 
was supplemented with 1 μmol/L RA (Sigma-Aldrich, 
Steinheim, Germany) instead of  LIF. Cells were cultured 
for 48 h before they were lysed and the proteins were 
extracted. For examining the effect of  CPX on the pro-
teome level, ESCs and maGSCs were treated with culture 
medium supplemented with 2 μmol/L CPX for 72 h.
Protein extraction
The protein extraction for 2-DE was performed as de-
scribed previously[7]. Briefly, 75% confluent cultures were 
trypsinized and washed three times with PBS. The cells 
were harvested by centrifugation at 200 × g for 10 min, the 
pellet was treated with 0.3-0.5 mL lysis buffer [9.5 mol/L 
urea, 2% CHAPS (w/v), 2% ampholytes (w/v), 1% DTT]. 
Ampholytes and DTT were added shortly before use. 
After adding the lysis buffer, the samples were incubated 
for 30 min at 4 ℃. For removing the cell debris, sample 
centrifugation was carried out at 13 000 × g and 4 ℃ for 
45 min. The supernatant was recentrifuged at 13 000 × g 
and 4 ℃ for an additional 45 min to get maximal purity. 
The resulting samples were used immediately or stored at 
-80 ℃ until use.
Protein precipitation
To reduce the salt contamination and to enrich the pro-
teins, methanol-chloroform-precipitation according to 
Wessel et al[33] was performed. Briefly, 0.4 mL of  metha-
nol (100%) was added to 0.1 mL aliquots of  protein 
samples and mixed together. 0.1 mL chloroform was 
added to the samples and the mixture was vortexed. Sub-
sequently 0.3 mL water was added and the solution was 
vortexed and centrifuged at 13 000 × g for 1 min. The 
aqueous layer was removed, and another 0.4 mL metha-
nol (100%) was added to the rest of  the chloroform and 
the interphase with the precipitated proteins. The sample 
was mixed and centrifuged for 2 min at 13 000 × g and 
the supernatant was removed. The pellet was vacuum 
dried and dissolved in lysis buffer.
Total protein concentration was determined using the 
Bio-Rad protein assay (Bio-Rad, Hercules, CA, United 
States) according to Bradford[34]. BSA (Sigma, Steinheim, 
Germany) was used as a standard.
2D gel electrophoresis (2-DE)
IPG strips (11 cm, pI 5-8) were passively rehydrated in 
185 μL solution containing 150 μg protein in a rehydra-
tion buffer (8 mol/L urea, 1% CHAPS, 1% DTT, 0.2% 
ampholytes, and a trace of  bromophenol blue) for 12 h. 
The IEF step was performed on the PROTEAN® IEF 
Cell (Bio-Rad, Hercules, CA, United States). Tempera-
ture-controlled at 20 ℃, the voltage was set to 500 V for 
1 h, increased to 1000 V for 1 h, 2000 V for 1 h and left 
at 8000 V until a total of  50 000 Vhours was reached. 
Prior to SDS-PAGE, the IPG strips were reduced for 
20 min at room temperature in SDS equilibration buffer 
containing 6 mol/L urea, 30% glycerol, 2% SDS 0.05 
mol/L Tris-HCl, and 2% DTT on a rocking table. The 
strips were subsequently alkylated in the same solution 
with 2.5% iodoacetamide substituted for DTT, and a 
trace of  bromophenol blue. For the SDS-PAGE, 12% 
BisTris Criterion precast gels (Bio-Rad, Hercules, CA, 
United States) were used according to manufacturer’s 
instructions. The gels were run at 150 V for 10 min fol-
lowed by 200 V until the bromophenol blue dye front 
had reached the bottom of  the gel.
Gel staining
For image analysis, 2-DE gels were fixed in a solution 
containing 50% methanol and 12% acetic acid overnight 
and fluorescent stained with Flamingo fluorescent gel 
stain (Bio-Rad, Hercules, CA, United States) for mini-
mum 5 h. After staining, gels were scanned at 50 μm 
resolution on a Fuji FLA-5100 scanner. The digitalized 
images were analyzed using Delta 2D 3.4 (Decodon, 
Braunschweig, Germany). For protein visualization, 2-DE 
gels were additionally stained with colloidal Coomassie 
blue, Roti-Blue (Roth, Karlsruhe, Germany) overnight.
2D-DIGE
Protein extraction and methanol-chloroform-precipitation 
11 January 26, 2013|Volume 5|Issue 1|WJSC|www.wjgnet.com
Dihazi GH et al . Proteomics of CPX treated stem cells
were performed as described above. The resulting pellet 
was dissolved in labeling buffer (30 mmol/L Tris-HCl 
pH 8.5, 9.5 mol/L urea, 2% CHAPS), centrifuged (5 min, 
13 000 × g), and the protein concentration of  the super-
natant was determined as described above. The prepara-
tion of  the CyDyes as well as the labeling reaction was 
followed according to the manufacturer’s protocol (GE 
Healthcare).
To avoid the dye-specific protein labeling, every pair 
of  protein samples from two independent cell extract 
preparations were processed in duplicate while swapping 
the dyes. Thereby four replicate gels were obtained, al-
lowing to monitor regulation factors down to twofold 
changes[35]. An internal standard consisting of  a mixture 
of  the samples under investigation was labeled with Cy2 
and included on all gels to facilitate gel matching, thereby 
eliminating artifacts from experimental variation. The 
three differentially labeled fractions were pooled. Rehy-
dration buffer (8 mol/L urea, 1% CHAPS, 13 mmol/L 
DTT and 1% ampholytes 3-10) was added to make up the 
volume to 185 μL prior to IEF. The 2-DE was performed 
as described above. The CyDye-labeled gels were scanned 
at 50 μm resolution on a Fuji FLA5100 scanner (Fuji Pho-
to, Kanagawa, Japan) with laser excitation light at 473 nm 
and long pass emission filter 510LP (Cy2), 532 nm and 
long pass emission filter 575LP (Cy3), and 635 nm and 
long pass emission filter 665LP (Cy5). Fluorescent images 
were acquired in 16-bit TIFF files format. Spot matching 
across gels and normalization based on the internal stan-
dard was performed with Delta2D software (Decodon, 
Greifswald, Germany). To analyze the significance of  pro-
tein regulation, a Student’s t-test was performed, and sta-
tistical significance was assumed for p values less than 0.01. 
For protein visualization, the 2-DE gels were post-stained 
with colloidal Coomassie blue (Roti-Blue) overnight. Dif-
ferentially regulated proteins were excised and processed 
for identification by mass spectrometry.
Protein identification
Manually excised gel plugs were subjected to an auto-
mated platform for the identification of  gel-separated 
proteins[36] as described in the framework of  recent 
DIGE-based[37] and large-scale proteome studies[38]. An 
Ultraflex MALDI-TOF-TOF mass spectrometer (Bruker 
Daltonik) was used to acquire both PMF and fragment 
ion spectra, resulting in confident protein identifica-
tions based on peptide mass and sequence information. 
Database searches in the Swiss-Prot primary sequence 
database restricted to the taxonomy mus musculus were 
performed using the MASCOT Software 2.2 (Matrix 
Science). Carboxamidomethylation of  Cys residues was 
specified as fixed and oxidation of  Met as variable modi-
fications. One trypsin missed cleavage was allowed. Mass 
tolerances were set to 100 ppm for PMF searches and 
to 100 ppm (precursor ions) and 0.7 Da (fragment ions) 
for MS/MS ion searches. The minimal requirement for 
accepting a protein as identified was at least one peptide 
sequence match above identity threshold in addition to at 
least 20 % sequence coverage in the PMF.
Bioinformatics 
The classification of  the identified proteins according 
to their main known/postulated functions was carried 
out using DAVID bioinformatics[39,40]. This classification 
together with the official gene symbol was used to inves-
tigate and categorize the gene ontology (GO)-annotations 
(biological processes and molecular functions). 
RESULTS
Comparative analysis of differentially expressed 
proteins in RA and CPX treated SCs by 2-DE and 
ontogenic classification
To explore proteome changes caused by CPX treatment, 
we treated ESCs as well as maGSCs with CPX for 72 h. 
In parallel, both cell types, ESC and maGSC, were treated 
with RA for 48 h. 2-DE was performed from these four 
different samples, as well as from the corresponding non-
treated cells (Figures 1-4). Proteins, which were found to 
be differentially expressed, were excised and subjected to 
in-gel-digestion and mass spectrometry analyses. A total 
of  316 spots were identified, which resulted in 125 non-
redundant proteins (Table 1). For further interpretation 
of  the data, only proteins, which were regulated in the 
same direction in ESCs and concurrently in maGSCs, 
were taken into consideration.
The identified proteins were classified using DAVID 
bioinformatics[39,40] focusing on its information consider-
ing the GO (Gene Ontology) annotations. The terms 
corresponding to the molecular function and biological 
process were regarded (Figures 5-7).
Comparison of the differently expressed proteins
Examination of  all of  the proteins, which expression was 
altered either by CPX or RA treatment, was performed 
regarding their involvement in biological processes. We 
found that seven proteins are involved in regulation of  
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Figure 1  Embryonic stem cells control vs ciclopirox olamine treated cells. 
Overlay of 2-DE gels of samples from ciclopirox olamine treated embryonic 
stem cells (ESCs) (orange) compared to control ESCs (blue). The identified 
proteins are indicated with the gene names. 
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transcription. Among these proteins Ube2n, Tardbp, 
Cbx3 and Hnrnpab were downregulated in CPX treated 
cells compared to control, whereas Nup62 was upregu-
lated in CPX treated cells compared to control (Table 2). 
Two other proteins Trim28 and Ruvbl1 were downregu-
lated in RA treated cells compared to control. Detailed 
information is given in Table 2 and the protein expres-
sion regulation folds are given in Tables 3-6.
When we looked at the molecular function of  the 
regulated proteins, we observed that a major part of  the 
proteins are involved in nucleotide binding (Table 7). Ap-
proximately half  of  these proteins were downregulated 
and the other half  was upregulated upon CPX treatment 
compared to RA treated cells. About 13 proteins are in-
volved in metal ion binding, of  these five proteins (Acy1, 
Uqcrc1, Sfrs1, Trim28, Glo1) are involved in transition 
metal ion binding, like Fe3+, which is known to be impor-
tant in case of  CPX, as CPX works as an inhibitor of  the 
iron-dependent enzymes due to its role as a chelator of  
intracellular iron. Three of  the proteins involved in tran-
sition metal ion binding (Sfrs1, Trim28 and Glo1), were 
up-regulated upon CPX treatment compared to RA-
treated cells.
Overall, it could be observed that most of  the pro-
teins of  interest were downregulated in either CPX or 
RA treated cells compared to control.
Treated cells compared to control
About 56 of  the 125 identified proteins showed different 
expression as a reaction to CPX treatment compared to 
control. Of  these, 14 proteins were upregulated as a reac-
tion to CPX treatment (Table 3), whereas 44 proteins were 
downregulated (Table 4). The expression of  52 proteins 
was found to be altered in both cell types, ESCs and maG-
SCs, under RA treatment compared to control (Tables 5 
and 6). Of  these proteins, 11 were upregulated and 41 
were downregulated as a reaction to RA treatment.
In both experiments the majority of  the regulated 
proteins were downregulated as a reaction to one of  
the treatments. Although mainly different proteins were 
regulated, bioinformatics analysis revealed that the down-
regulated proteins in both experiments are primarily 
involved in the same molecular functions (Figure 5). The 
downregulated proteins upon CPX treatment are mainly 
involved in nucleotide binding, GTP binding, peptidase 
activity and metal ion binding, particularly magnesium 
ion binding. The proteins which were downregulated 
upon RA treatment are involved in transition metal ion 
binding instead of  magnesium ion binding, and further-
more involved in enzyme binding. Proteins, which were 
upregulated upon CPX treatment, are mainly involved in 
nucleotide binding, whereas proteins which were upregu-
lated upon RA treatment are involved in nucleotide and 
metal ion binding. 
When we look at the involvement of  the regulated 
proteins in biological processes, more differences were 
observed (Figure 6). Both treatments showed downregu-
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Figure 4  Multipotent adult germline stem cell control vs ciclopirox 
olamine treated cells. Overlay of 2-DE gels of samples from ciclopirox olamine 
treated Multipotent adult germline stem cells (maGSCs) (orange) compared to 
retinoic acid treated maGSCs (blue). The identified proteins are indicated with 
the gene names.
pH 5 IEF pH 8
Figure 3  Embryonic stem cell control vs ciclopirox olamine treated cells. 
Overlay of 2-DE gels of samples from ciclopirox olamine treated embryonic 
stem cells (ESCs) (orange) compared to retinoic acid treated ESCs (blue). The 
identified proteins are indicated with the gene names.
pH 5 IEF pH 8
Figure 2  Multipotent adult germline stem cells control vs ciclopirox ol-
amine treated cells. Overlay of 2-DE gels of samples from ciclopirox olamine 
treated multipotent adult germline stem cells (maGSCs) (orange) compared 
to control maGSCs (blue). The identified proteins are indicated with the gene 
names.
Dihazi GH et al . Proteomics of CPX treated stem cells
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Table 1  Non-redundant proteins













Low molecular weight phosphotyrosine protein 
phosphatase 
Acp1 PPAC_MOUSE 18 636 6.4   6 65   80 24
Actin, cytoplasmic 1 Actb ACTB_MOUSE 42 052 5.2 170 70 312 15
Aminoacylase-1 Acy1 ACY1_MOUSE 45 80 5. 167 56   44   5
Aldose reductase Akr1b1 ALDR_MOUSE 36 052 6. 128 43 136 10
Aldehyde dehydrogenase, mitochondrial Aldh2 ALDH2_MOUSE 57 015 8.6 221 54 131   7
Annexin A3 Anxa3 ANXA3_MOUSE 36 520 5.2   84 47 111 14
Adenine phosphoribosyltransferase Aprt APT_MOUSE 1 883 6.4   88 67 216 27
Rho GDP-dissociation inhibitor 1 Arhgdia GDIR1_MOUSE 23 450      5 123 54   66 11
ATP synthase subunit α, mitochondrial Atp5a1 ATPA_MOUSE 5 830 .7 100 28   53   4
ATP synthase subunit β, mitochondrial Atp5b ATPB_MOUSE 56 265 5.1   0 30 167 10
ATP synthase subunit d, mitochondrial Atp5h ATP5H_MOUSE 18 75 5.4 122 70 16 36
F-actin-capping protein subunit α-2 Capza2 CAZA2_MOUSE 33 118 5.5 148 6   1   
F-actin-capping protein subunit β Capzb CAPZB_MOUSE 31 611 5.4 117 61 12   8
Chromobox protein homolog 3 Cbx3 CBX3_MOUSE 21 013      5   38 36   67   6
T-complex protein 1 subunit β Cct2 TCPB_MOUSE 57 783      6 248 61   75   
T-complex protein 1 subunit epsilon Cct5 TCPE_MOUSE 60 042 5.7 186 60 138   6
Cofilin-1 Cfl1 COF1_MOUSE 18 776 .1   5 45   87 13
UMP-CMP kinase Cmpk1 KCY_MOUSE 22 37 5.6   74 52   2 10
Coactosin-like protein Cotl1 COTL1_MOUSE 16 048 5.1   86 60 116 14
Cathepsin D Ctsd CATD_MOUSE 45 381 6. 160 41   5   4
Dihydrolipoyl dehydrogenase, mitochondrial Dld DLDH_MOUSE 54 751       112 48   81   2
Elongation factor 1-α1 Eef1a1 EF1A1_MOUSE 50 424 .7   68 34 115   8
Elongation factor 1-d Eef1d EF1D_MOUSE 31 388 4.8   86 54   7   
Elongation factor 2 Eef2 EF2_MOUSE 6 222 6.4   52 26   2   1
Eukaryotic translation initiation factor 3 subunit F Eif3f EIF3F_MOUSE 38 00 5.2 10 45 106 14
Eukaryotic translation initiation factor 3 subunit G Eif3g EIF3G_MOUSE 35 01 5.6   54 35   23   7
Eukaryotic translation initiation factor 3 subunit I Eif3i EIF3I_MOUSE 36 837 5.3 228 78   8 16
Eukaryotic translation initiation factor 4H Eif4h IF4H_MOUSE 27 381 7.5   83 51   65   8
Eukaryotic translation initiation factor 5A-1 Eif5a IF5A1_MOUSE 17 04 4. 115 58 170 22
α-enolase Eno1 ENOA_MOUSE 47 453 6.4 183 64 170 13
Electron transfer flavoprotein subunit α, mitochondrial Etfa ETFA_MOUSE 35 330 .5 138 5 100   
Fatty acid-binding protein, heart Fabp3 FABPH_MOUSE 14 810 6.1   86 77 212 3
Peptidyl-prolyl cis-trans isomerase FKBP4 Fkbp4 FKBP4_MOUSE 51 3 5.4 122 38 168   
Fascin Fscn1 FSCN1_MOUSE 55 215 6.5 12 45   26   6
Glyceraldehyde-3-phosphate dehydrogenase Gapdh G3P_MOUSE 36 072 .2   62 38   40   8
Lactoylglutathione lyase Glo1 LGUL_MOUSE 20 67 5.1 134 66 114 20
Glyoxalase domain-containing protein 4 Glod4 GLOD4_MOUSE 33 581 5.2 167 6 115 13
Glutamate dehydrogenase 1, mitochondrial Glud1 DHE3_MOUSE 61 640 8.8   70 37   60   5
Guanine nucleotide-binding protein subunit β-2-like 1 Gnb2l1 GBLP_MOUSE 35 511 8. 116 55   20   5
Growth factor receptor-bound protein 2 Grb2 GRB2_MOUSE 25 336 5.   73 54   36 17
Histone H2B type 1-B Hist1h2bb H2B1B_MOUSE 13 44    10.8   52 41   3 1
Histone H2A type 2-C Hist2h2ac H2A2C_MOUSE 13 80    11.4   50 55   67 12
Heterogeneous nuclear ribonucleoprotein A/B Hnrnpab ROAA_MOUSE 30 26 8.7   83 30 107   5
Heterogeneous nuclear ribonucleoproteins C1/C2 Hnrnpc HNRPC_MOUSE 34 421 4.8   57 32   57   6
Heterogeneous nuclear ribonucleoprotein F Hnrnpf HNRPF_MOUSE 46 043 5.2 163 56 207 12
Heterogeneous nuclear ribonucleoprotein H Hnrnph1 HNRH1_MOUSE 4 454 5. 166 61 134 15
Heterogeneous nuclear ribonucleoprotein K Hnrnpk HNRPK_MOUSE 51 230 5.3 144 46 251 11
Heat shock protein HSP 0-α Hsp0aa1 HS0A_MOUSE 85 134 4.8 131 31 130   5
Heat shock protein HSP 0-β Hsp0ab1 HS0B_MOUSE 83 615 4.8   62 25   78   6
Heat shock 70 kDa protein 4 Hspa4 HSP74_MOUSE 4 872      5 242 54 102   3
78 kDa glucose-regulated protein Hspa5 GRP78_MOUSE 72 42 4.   78 25 122   5
Heat shock cognate 71 kDa protein Hspa8 HSP7C_MOUSE 71 055 5.2 234 58 154   4
Stress-70 protein, mitochondrial Hspa GRP75_MOUSE 73 768 5.8 21 50 272   7
Heat shock protein β-1 Hspb1 HSPB1_MOUSE 23 057 6.1 144 55 344 24
60 kDa heat shock protein, mitochondrial Hspd1 CH60_MOUSE 61 088 5.8 334 6 232 10
Isocitrate dehydrogenase (NAD) subunit α, 
mitochondrial 
Idh3a IDH3A_MOUSE 40 06 6.3   70 31 158 12
Inosine-5'-monophosphate dehydrogenase 2 Impdh2 IMDH2_MOUSE 56 17      7 173 50 107   7
Inosine triphosphate pyrophosphatase Itpa ITPA_MOUSE 22 225 5.5   84 72 128 15
Keratin, type Ⅰ cytoskeletal 18 Krt18 K1C18_MOUSE 47 50 5.1 1 65   58   
Keratin, type Ⅱ cytoskeletal 7 Krt7 K2C7_MOUSE 50 678 5.6 137 52   55   4
Keratin, type Ⅱ cytoskeletal 8 Krt8 K2C8_MOUSE 54 531 5.6 245 55 237   
Cytosol aminopeptidase Lap3 AMPL_MOUSE 56 505 8.7 126 47   58   5
L-lactate dehydrogenase B chain Ldhb LDHB_MOUSE 36 834 5.6   84 46   30   6
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Galectin-1 Lgals1 LEG1_MOUSE 15 18 5.2 10 70 172 25
Galectin-2 Lgals2 LEG2_MOUSE 14 84 7. 120 88   60 14
Lamin-B1 Lmnb1 LMNB1_MOUSE 66 73      5 265 60 134   5
α-2-macroglobulin receptor-associated protein Lrpap1 AMRP_MOUSE 42 18 7. 13 4 177 14
S-adenosylmethionine synthase isoform type-2 Mat2a METK2_MOUSE 44 003      6   73 41   5   3
28S ribosomal protein S22, mitochondrial Mrps22 RT22_MOUSE 41 281 .2 112 45   7   
Myosin- Myh MYH_MOUSE   227 42 5.4   73 15 103   2
Nucleolin Ncl NUCL_MOUSE 76 734 4.5 113 26 17   7
Omega-amidase NIT2 Nit2 NIT2_MOUSE 30 825 6.5 112 5   75   
Nucleoside diphosphate kinase A Nme1 NDKA_MOUSE 17 311 7.7 125 72 223 30
Nucleoside diphosphate kinase B Nme2 NDKB_MOUSE 17 466 7.8 160 84 287 30
Nucleophosmin Npm1 NPM_MOUSE 32 711 4.5   53 33 136 10
Nuclear pore complex protein Nup54 Nup54 NUP54_MOUSE 55 812 6.6   55 21   23   3
Nuclear pore glycoprotein p62 Nup62 NUP62_MOUSE 53 336 5.1 13   43   5
Ornithine aminotransferase, mitochondrial Oat OAT_MOUSE 48 723 6.2 174 64 125   
Poly(rC)-binding protein 1 Pcbp1 PCBP1_MOUSE 37 87 6.8 175 6 115 12
Protein disulfide-isomerase A3 Pdia3 PDIA3_MOUSE 57 0 5.8 254 55   0   5
Protein disulfide-isomerase A6 Pdia6 PDIA6_MOUSE 48 46 4.   75 40   47   2
PDZ and LIM domain protein 1 Pdlim1 PDLI1_MOUSE 36 208 6.4 200 73   56   7
Phosphatidylethanolamine-binding protein 1 Pebp1 PEBP1_MOUSE 20 88 5.1 130 7 107 11
Phosphoglycerate mutase 1 Pgam1 PGAM1_MOUSE 28 28 6.8 157 66 12 21
Phosphoglycerate kinase 1 Pgk1 PGK1_MOUSE 44 21       136 52 128   7
6-phosphogluconolactonase Pgls 6PGL_MOUSE 27 465 5.5 102 4 148 17
Pyruvate kinase isozymes M1/M2 Pkm2 KPYM_MOUSE 58 378 7. 178 4 106   
Purine nucleoside phosphorylase Pnp PNPH_MOUSE 32 541 5.8 11 67 138 13
Inorganic pyrophosphatase Ppa1 IPYR_MOUSE 33 102 5.3 126 66   26   7
Peroxiredoxin-2 Prdx2 PRDX2_MOUSE 21 36 5.1 103 62 285 22
Peroxiredoxin-6 Prdx6 PRDX6_MOUSE 24 6 5.6 156 67 101 17
Proteasome subunit α type-1 Psma1 PSA1_MOUSE 2 813      6   71 52 140 17
Proteasome subunit α type-6 Psma6 PSA6_MOUSE 27 811 6.4   72 38 108 10
Proteasome subunit β type-3 Psmb3 PSB3_MOUSE 23 235 6.2 110 51 187 30
Proteasome subunit β type-4 Psmb4 PSB4_MOUSE 2 211 5.3   60 42 10 10
26S protease regulatory subunit 7 Psmc2 PRS7_MOUSE 4 016 5.6 166 60   72   8
26S protease regulatory subunit 6B Psmc4 PRS6B_MOUSE 47 366      5 144 55 10   
GTP-binding nuclear protein Ran Ran RAN_MOUSE 24 57 7.8 124 51 13 11
40S ribosomal protein S12 Rps12 RS12_MOUSE 14 858 7.7   77 62   5 11
RuvB-like 1 Ruvbl1 RUVB1_MOUSE 50 524      6   61 35 106 10
Protein S100-A11 S100a11 S10AB_MOUSE 11 247 5.1 36 147 27
Splicing factor, arginine/serine-rich 1 Sfrs1 SFRS1_MOUSE 27 842    10.8   80 43 156 18
Splicing factor, arginine/serine-rich 3 Sfrs3 SFRS3_MOUSE 1 546    12.3   87 14
Serine hydroxymethyltransferase, cytosolic Shmt1 GLYC_MOUSE 53 065 6.5   8 43   1   2
Superoxide dismutase [Cu-Zn] Sod1 SODC_MOUSE 16 104      6   83 45 126 31
Spermidine synthase Srm SPEE_MOUSE 34 543 5.2 141 73 12 15
Stress-induced-phosphoprotein 1 Stip1 STIP1_MOUSE 63 170 6.4 184 55   8   4
Stathmin Stmn1 STMN1_MOUSE 17 264 5.7   28 24   6   8
Stomatin-like protein 2 Stoml2 STML2_MOUSE 38 475 .5 144 61 165 15
TAR DNA-binding protein 43 Tardbp TADBP_MOUSE 44 18 6.3   68 30 107   7
T-complex protein 1 subunit α Tcp1 TCPA_MOUSE 60 867 5.8   61 27   28   4
Transcription intermediary factor 1-β Trim28 TIF1B_MOUSE 0 558 5.4 10 13   4
Tubulin α-1B chain Tuba1b TBA1B_MOUSE 50 804 4.8 128 3 152   
Tubulin α-1C chain Tuba1c TBA1C_MOUSE 50 562 4.8   53 24   52   6
Tubulin β-2A chain Tubb2a TBB2A_MOUSE 50 274 4.6 126 55 111 11
Tubulin β-2C chain Tubb2c TBB2C_MOUSE 50 255 4.6 150 56   4   8
Tubulin β-5 chain Tubb5 TBB5_MOUSE 50 05 4.6 16 57 237   
Thioredoxin Txn THIO_MOUSE 12 010 4.6   63 67   2 22
Thioredoxin-like protein 1 Txnl1 TXNL1_MOUSE 32 616 4.7 144 78   3   2
Ubiquitin-conjugating enzyme E2 N Ube2n UBE2N_MOUSE 17 184 6.2 11 71   20   6
Ubiquitin carboxyl-terminal hydrolase isozyme L1 Uchl1 UCHL1_MOUSE 25 165      5   77 64   16   8
Cytochrome b-c1 complex subunit 1, mitochondrial Uqcrc1 QCR1_MOUSE 53 420 5.7   5 40   46   6
Transitional endoplasmic reticulum ATPase Vcp TERA_MOUSE 8 50      5 310 61   40   5
Voltage-dependent anion-selective channel protein 1 Vdac1 VDAC1_MOUSE 32 502 .2 15 57   80 24
Vimentin Vim VIME_MOUSE 53 712 4. 218 64   47   8
CPI: Calculated isoelectric point; PMF: Peptide mass fingerprint; MS/MS: Tandem mass spectrometry.
lation of  proteins involved in protein complex biogenesis, 
nucleotide biosynthetic process, cell death and positive 
regulation of  biosynthetic process. Additionally, proteins 
involved in proteolysis and positive regulation of  protein 
metabolic process were downregulated in SCs upon CPX 
treatment. Proteins which were downregulated in SCs 
upon RA treatment are, among others, involved in cell 
cycle, RNA processing, glycolysis and negative regulation 
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Table 2  Gene Ontology functional annotation of proteins which were regulated in this experiment according to their involvement 
in different biological processes
Biological process Proteins CPX > RA CPX < RA CPX > c CPX < c RA > c RA < c
Monosaccharide metabolic/
catabolic processes
  5 Pgls Eno1 Eno1 Eno1 




nucleotide, and nucleic acid 
biosynthetic processes 
  7 Atp5a1 Aprt Atp5a1 Aprt Nme2 Aprt





RNA and mRNA processing   6 Sfrs1 Hnrnpk Hnrnpc 
Tardbp Sfrs3
Pcbp1




Embryonic development   5 Sfrs1 Psmc4 Atp5a1 Eno1 Myh Eno1
Eno1 Eno1 Myh Atp5a1 Psmc4
Gene expression 16 Trim28  Rps12 Eif3f Eef1a1  Sfrs3 











Cell morphogenesis involved 
in differentiation
  4 Trim28 Myh Uchl1 Myh Stmn1
Hnrnpab Trim28
Regulation of cell 
proliferation
  4 Nup62 Nme2 Nme2 Npm1
Pnp
Regulation of signal 
transduction
  4 Nup62 Ube2n Npm1
Hspa5
Ciclopirox olamine (CPX) > retinoic acid (RA): Proteins which were more than 2-fold higher expressed in CPX-treated cells compared to RA-treated cells; 
CPX < RA: Proteins which were more than 2-fold higher expressed in RA-treated cells compared to CPX-treated cells; CPX > c: Proteins which were 
more than 2-fold higher expressed in CPX-treated cells compared to control; CPX < c: Proteins which were more than 2-fold higher expressed in control 
compared to CPX-treated cells; RA > c: Proteins which were more than 2-fold higher expressed in RA-treated cells compared to control; RA < c: Proteins 
which were more than 2-fold higher expressed in control compared to RA-treated cells.
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of  protein metabolic process.
Proteins which were upregulated in SCs upon CPX 
treatment are involved in nucleotide binding, regulation 
of  cell death and protein transport, whereas proteins 
which were upregulated upon RA treatment are involved 
in nucleotide binding, metal ion binding and proteolysis.
Proteins in CPX treated cells compared to RA treated 
cells
When the proteins in RA treated SCs were compared to 
CPX treated SCs, we observed that 54 proteins are dif-
ferently regulated (Tables 8 and 9). Of  these proteins, 31 
were upregulated and 26 downregulated upon CPX treat-
ment. In some cases, different forms of  one protein, e.g., 
Actb, Eno1, and Hsp90aa1 were observed and showed 
different regulation. 
The bioinformatics analysis of  these proteins, focus-
sing on biological processes, showed involvement of  the 
proteins in different categories (Figure 7). Proteins which 
were downregulated in CPX treated cells are involved 
in processes like protein complex biogenesis, nucleotide 
biosynthetic process, proteolysis, intracellular transport 
and regulation of  cell death. Proteins which were down-
regulated as a reaction to RA treatment are involved in 
protein complex biogenesis, cell death, positive regulation 
of  biosynthetic process, response to organic substance, 
glycolysis, anti-apoptosis and phosphorylation.
To get a better focus on proteins, which may play a 
key role in proliferation, we also focussed on proteins, 
which showed contrary regulation upon CPX treatment 
and RA treatment compared to control. This resulted 
in 15 proteins, of  which eight were upregulated upon 
CPX treatment and concurrently downregulated upon 
RA treatment compared to control, and seven proteins, 
Dihazi GH et al . Proteomics of CPX treated stem cells
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Figure 5  Molecular function. Classification of the downregulated proteins upon treatment with ciclopirox olamine (CPX) (A) or retinoic acid (RA) (B) according to 
their molecular functions.
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Figure 6  Biological process. Classification of the downregulated proteins upon treatment with ciclopirox olamine (CPX) (A) or retinoic acid (RA) (B) according to 
their biological processes.
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which were downregulated upon CPX treatment and 
concurrently upregulated upon RA treatment compared 
to control (proteins marked by asterisk in Tables 8 and 9).
Bioinformatics analysis of  the proteins, which were 
downregulated upon CPX treatment along with upregu-
lated upon RA treatment were primarily involved in meta-
bolic processes (Nme2, Hsp90aa1, Psmc4, Rps12, Cct2 
and Eno1) like protein folding (Hsp90aa1, Cct2), whereas 
proteins, which were upregulated upon CPX-treatment 
and concurrently downregulated upon RA-treatment were 
additionally involved in developmental processes (Psmc4, 
Eno1) and transport/localization (Vdac1, Hspa9).
Analysis of  the molecular function of  the differently reg-
ulated proteins upon CPX and RA treatment showed their 
important role in nucleotide binding (Nme2, Hsp90aa1, 
Psmc4, Hspa4, Cct2, Actb, Pkm2, Hspa5, Vdac1 and 
Hspa9) and metal ion binding (Pkm2, S100a11, Eno1).
DISCUSSION
CPX is a synthetic antifungal drug, which is currently 
used for the treatment of  superficial mycoses[41]. Since 
two decades CPX has also been used as an antitumor 
agent[42]. It has been shown that CPX can be used to treat 
solid tumors due to its strong antiangiogenic activity[43,23]. 
CPX might inhibit the cell proliferation and work as an 
antitumor agent due to its iron chelating function, as 
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Figure 7  Biological process. Classification of the differently regulated proteins upon treatment with ciclopirox olamine (CPX) (A) or retinoic acid (RA) (B) according 
to their biological processes.
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1The proteins are referred to in the text and following tables. CPX: Ci-
clopirox olamine; ESC: Embryonic stem cell; maGSC: Multipotent adult 
germline stem cell.
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a recent study, we investigated the effect of  CPX on the 
cellular viability and proliferation of  SCs. The study dem-
onstrated that in contrast to RA, CPX treatment resulted 
in a reversible antiproliferative effect[8]. The present study 
was conducted to understand the anti-proliferative effect 
of  CPX on stem cells in terms of  proteins and molecular 
processes which are involved in its mode of  action.
With proteomic analysis of  ESCs and maGSCs treated 
with CPX and RA, we could identify more than 90 single 
proteins which were differently expressed in both cell 
lines. Bioinformatics analysis of  the regulated proteins 
demonstrated their involvement in various biological 
processes. To our interest, a number of  proteins have po-
tential roles in the regulation of  cell proliferation either 
directly or indirectly. 
One of  the possible mechanisms of  CPX action on 
Table 4  Proteins which are downregulated upon ciclopirox 
olamine treatment compared to control
k/CPX
ESC maGSC
Acp1   1.2 6.01
Acy11   1.38 2.81
Akr1b1   2.07 13.44
Aprt1   4.80   3.60
Atp5a11   3.50   1.21
Capzb   3.04   2.35
Cbx31   1.72   2.12
Cct21 12.00   1.28
Cct51   1.06   2.02
Eef1a11   2.47   1.74
Eef1d1   1.46   2.03
Eif5a1   1.31   2.07
Eno11   3.56   1.60
Fscn1   3.31   1.4
Glod4   3.35   1.60
Gnb2l1   2.61 12.2
Hist1h2bb   2.31   2.10
Hist2h2ac 17.33 67.0
Hnrnpab1   2.41   3.36
Hnrnpk1   2.00   1.17
Hsp0aa11   1.1   6.7
Hsp0aa11   1.84   3.02
Hspa41   3.28   1.51
Hspa4   1.13   3.14
Hspa8   1.74   7.17
Hspd1   1.67   3.07
Impdh21   2.5   2.13
Impdh21 > 100 27.4
Krt181   2.31   1.44
Lgals2   2.82   8.45
Ncl1   1.33   2.61
Nit2   1.24   2.13
Nme11   6.25   1.56
Nme21   4.77   4.51
Pcbp11   2.21   1.64
Pkm21   3.75   3.27
Pnp1   1.20   2.62
Psmb41   1.01   2.32
Ruvbl11   1.02   2.14
Srm   1.64   3.63
Shmt11 > 100 > 100
Tardbp1   1.38   3.52
Tcp1   1.47   3.76
Tuba1c1   1.87   3.11
Tubb2c1   1.38   3.41
Ube2n1   1.31   6.45
Uchl11   2.66   1.66
1The proteins are referred to in the text and following tables. CPX: Ci-
clopirox olamine; ESC: Embryonic stem cell; maGSC: Multipotent adult 
germline stem cell.
Table 5  Proteins which are downregulated upon retinoic acid 























































1The proteins are referred to in the text and following tables. RA: Retinoic 
acid; ESC: Embryonic stem cell; maGSC: Multipotent adult germline stem 
cell.
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cell proliferation is through controlling the progression 
of  the cell cycle[44]. We identified a number of  proteins 
which are involved in cell cycle processes. Ruvbl1 is one 
of  the differentially regulated proteins which is involved 
in cell cycle processes, gene expression and transcription 
regulation. It was found to be downregulated in CPX and 
RA treated cells compared to control (Figure 8). Ruvbl1 
is an evolutionarily highly conserved eukaryotic protein 
belonging to the AAA+ family of  ATPase’s[45]. It plays 
an important role in various cell cycle processes such as 
chromatin remodeling[46], gene activation[47], transcrip-
tional regulation, DNA repair and transcription factor 
c-Myc[48]. It also controls Wnt signaling pathway through 
transcription-associated protein β-catenin[49,50]. Another 
protein, which was higher expressed in CPX treated cells 
compared to RA treated cells, is Trim28. Trim28 is in-









ESC C ESC RA ESC CPX maGSC C maGSC RA maGSC CPX
Figure 8  Enlargement of the gel spots of some proteins of interest. ESC: Embryonic stem cell; maGSC: Multipotent adult germline stem cell; CPX: Ciclopirox 
olamine; RA: Retinoic acid.
Table 6  Proteins which are upregulated upon retinoic acid 
treatment compared to control
RA/k
ESC maGSC
Cct2 1.14   2.16
Hspa4 3.6   2.47
Krt71 1.01 38.11
Krt8 1.7   1.78
Myh1 3.06   3.24
Nme11 2.52   3.81
Nme21 1.20   2.48
Pdia6 1.72 20.48
Psmc41 2.17   2.17
Vcp 8.30   4.13
Vim1 3.85   1.16
1The proteins are referred to in the text and following tables. RA: Retinoic 
acid; ESC: Embryonic stem cell; maGSC: Multipotent adult germline stem cell.
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expression through its ability to bind to DNA through in-
teraction with a KRAB-ZFP protein. Other proteins, like 
Cbx3, Tardbp, and Hnrnpab, which are important in gene 
expression and regulation of  transcription, were down-
regulated due to treatment with CPX. Tardpb is a DNA 
and RNA-binding protein, which regulates transcription 
and splicing. It is also involved in the regulation of  CFTR 
(Cystic fibrosis transmembrane conductance regulator), 
microRNA biogenesis, apoptosis and cell division. It can 
repress HIV-1 transcription by binding to the HIV-1 long 
terminal repeat. Cbx3 seems to be involved in transcrip-
tional silencing in heterochromatin-like complexes. It 
recognizes and binds histone H3 tails methylated at K9, 
which leads to epigenetic repression. It is suggested that 
these proteins, which are involved in cell cycle processes, 
transcription regulation and gene expression, might be 
potential candidates for cell proliferation regulation and 
their repression through down-regulation might result in 
cell cycle stop without impact on stem cell pluripotency.
Proteins, which are involved in nucleotide biosyn-
thetic process and proteolysis, were downregulated in 
CPX treated cells compared to control, as well as in RA 
treated cells (Figures 6A and 7A). Nucleoside diphospha-
tase kinases A and B (Nme1 and Nme2) are some of  the 
Table 7  Gene Ontology functional annotation of proteins which were regulated in this experiment according to their involvement 
in different molecular function
Molecular function Proteins CPX > RA CPX < RA CPX > c CPX < c RA > c RA < c
Nucleotide binding 41 Hsp0ab1 Atp5b Tubb2a Cct2 Cct2 Ldhb
Fkbp4 Cct2 Etfa Tardbp Hspa4 Fkbp4
Tubb5 Tardbp Hspa Hspa4 Myh Tubb5
Hspa5 Hspa4 Actb Tuba1c Nme2 Hnrnpc
Tubb1b Actb Myh Hspa8 Vcp Hspa5
Gapdh Hsp0aa1 Vdac1 Hnrnpab Psmc4 Tuba1c
Etfa Ncl Atp5a1 Eef1a1 Nme1 Hspa8
Hspa Aprt Hspd1 Tcp1 Actb
Actb Nme2 Hsp0aa1 Hsp0aa1
Hsp0aa1 Vcp Ncl Ncl
Sfrs1 Psmc4 Aprt Sfrs3
Vdac1 Nme1 Ube2n Aprt







GTP binding 8 Fkbp4 Nme1 Tubb2a Eef1a1 Nme1 Fkbp4
Tubb5 Nme1 Tubb5
Tuba1b Tuba1c Tuba1c
ATPase activity 8 Atp5a1 Vcp Atp5a1 Atp5a1 Vcp Atp5a1
Psmc4 Myh Hspa8 Psmc4 Atp5h
Atp5b Myh Hspa8
Psmc2
Enzyme binding 8 Actb Actb Actb Gnb2l1 Vim Actb




Cofactor binding 5 Gapdh Etfa Shmt1 Ldhb
Etfa Shmt1
Peptidase activity 6 Ctsd Uchl1 Ctsd Psmb4 Psmb4
Eno1 Eno1 Acy1 Uqcrc1
Uchl1 Acy1 
Eno1 Eno1
Metal ion binding 13 Trim28 Atp5b Acy1 Pdia6 Acy1
Sfrs1 Pdia6 Nme2 Nme2 Uqcrc1
Pkm2 Nme2  Nme1 Nme1 Trim28 Pkm2
Glo1 Nme1 Pkm2 Glo1
Eno1 Eno1 Impdh2 Impdh2 
Eno1 Eno1
Ciclopirox olamine (CPX) > Retinoic acid (RA): Proteins which were more than 2-fold higher expressed in CPX-treated cells compared to RA-treated 
cells; CPX < RA: Proteins which were more than 2-fold higher expressed in RA-treated cells compared to CPX-treated cells; CPX > c: Proteins which were 
more than 2-fold higher expressed in CPX-treated cells compared to control; CPX < c: Proteins which were more than 2-fold higher expressed in control 
compared to CPX-treated cells; RA > c: Proteins which were more than 2-fold higher expressed in RA-treated cells compared to control; RA < c: Proteins 
which were more than 2-fold higher expressed in control compared to RA-treated cells.
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proteins which are involved in nucleotide biosynthetic 
process. These proteins are known to be involved in the 
synthesis of  nucleoside triphosphatases[51] as well as in 
cell proliferation[52], differentiation[53] and development[54], 
signal transduction, G protein-coupled receptor endocy-
tosis and gene expression. Nme1 was downregulated in 
CPX treated cells compared to control and RA treated 
cells (Figure 8). This may explain the slowdown of  the 
proliferation of  CPX treated SCs. Impdh2 is a rate limit-
ing enzyme in the de novo synthesis of  guanine nucleotides 
and is therefore involved in the regulation of  cell growth 
and differentiation[55-58]. It may have a role in the develop-
ment of  malignancy and the growth progression of  some 
tumors. Impdh2 was downregulated in CPX treated cells 
compared to control (Figure 8).
Proteins which were involved in cell death, positive 
regulation of  biosynthetic process, response to organic 
substance, glycolysis, anti-apoptosis, and phosphorylation 
were downregulated in RA treated cells compared to con-
trol and CPX treated cells (Figures 6B and 7B).
Analysis of  the molecular function of  the differently 
expressed proteins demonstrated a potential involve-
ment of  some of  these in metal ion binding, mainly iron 
binding. Cazzola et al[59] in 1990 established that iron is 
essential for proliferation, DNA synthesis and repair and 
mitochondrial electron transport. Therefore, it is assumed 
that CPX can stop the cell proliferation by regulating the 
expression of  iron binding proteins.
The present study could give some insights into the 
mode of  action of  CPX in terms of  expression regula-
Table 8  Proteins which are upregulated in stem cells upon 













































1The proteins are referred to in the text and following tables; 2The protein 
was not identified in embryonic stem cells. Proteins, which are assigned 
an asterisk, were upregulated upon ciclopirox olamine (CPX) treatment 
compared to control and concurrently downregulated upon retinoic acid 
(RA) treatment compared to control. ESC: Embryonic stem cell; maGSC: 
Multipotent adult germline stem cell.
Table 9  Proteins which are downregulated upon ciclopirox 




Actb1   2.17     1.10
Aldh2   2.61     2.17
Aldh2   2.43     1.21
Aprt1   2.20     1.42
Atp5b   1.15     2.17
Capzb   2.7     2.07
Cct2*1 13.70     2.77
Eno11   2.48     2.02
Eno11   2.71     1.51
Fscn1   2.20     2.14
Gnb2l1   1.81     2.24
Hist1h2bb   7.53     1.62
Hist2h2ac   3.8 211.81
Hnrnpk   2.37     1.58
Hsp0aa1*1   2.6     6.36
Hsp0aa1   6.36     4.33
Hspa4*1 12.8     3.72
Hspa4   1.35     3.42
Krt7 > 100     1.14
Krt18*1   4.04     1.76
Ncl   1.80     3.48
Nme11   2.63     1.57
Nme2*1   5.72   11.15
Pdia6   1.74     6.33
Psmc21   2.87     1.20
Psmc4*1   3.06     2.26
Rps12*1 2     2.05
Tardbp   1.11     3.85
Uchl11   2.02     1.10
Vcp1   8.4     2.57
1The proteins are referred to in the text and following tables; 2The protein 
was not identified in embryonic stem cells. Proteins, which are assigned 
an asterisk, were downregulated upon ciclopirox olamine (CPX) treatment 
compared to control and concurrently upregulated upon retinoic acid (RA) 
treatment compared to control. ESC: Embryonic stem cell; maGSC: Multi-
potent adult germline stem cell.
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tion of  various proteins. It not only shed light on the 
previously discussed roles of  CPX, but could also pro-
vide some further insight into their mechanism. We could 
identify some potential candidates which can effect the 
cell proliferation directly or indirectly through other cel-
lular processes. By understanding the mode of  action of  
CPX, this study may provide new aspect that will help in 
the future strategy to improve therapeutic intervention in 
the treatment with CPX.
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